Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04265872 · ClinicalTrials.gov registry record · Early Phase 1
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
A Early Phase 1 study of Breast Cancer, sponsored by Baylor Research Institute.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04265872: Recruiting Early Phase 1 study of Breast Cancer, sponsored by Baylor Research Institute.
NCT04265872 is a Early Phase 1 study of Breast Cancer that is actively recruiting participants, run by Baylor Research Institute. The registered enrollment target is 20 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04265872, a Early Phase 1 study of Breast Cancer, is actively recruiting participants, sponsored by Baylor Research Institute.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in metastatic TNBC leading at the time of disease progression to metastases that are HR-deficient and sensitive to pembrolizumab and cisplatin therapy. The trial will include in depth analysis of the patients' TNBC genome and phosphoproteome to evaluate HR-proficiency and deficiency, and nuclear proteins that drive NHEJ, before and upon progression with bortezomib therapy.
Primary Outcome
objective response rate will be calculated by defining the proportion of patients who have a complete or partial response to the study therapy, as determined by the treating physician
Conditions Studied
Interventions
- DRUG Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis
Study Locations (1)
Texas
- Baylor University Medical Center, Baylor Charles A Sammons Cancer Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2027-03-31 |
| Phase | Early Phase 1 |
What NCT04265872 shows while recruiting
NCT04265872 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis is the first listed.
NCT04265872 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04265872 about?
NCT04265872 is a clinical study titled "Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC". The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in metastatic TNBC leading at the time of disease progression to metastases that are HR-deficient and sensitive to pembrolizumab and cisplatin therapy. The trial will include in depth analysis of the patients' ...
What is the current status of trial NCT04265872?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2020-10-15. Estimated completion is 2027-03-31.
What conditions does trial NCT04265872 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT04265872?
The interventions under investigation include: Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis (DRUG).
Who is sponsoring clinical trial NCT04265872?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04265872 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04265872's enrollment target sits among peer trials
20 1079th of 1224 higher than 112 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
RECRUITING · Early Phase 1
-
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
RECRUITING · Early Phase 1
-
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
RECRUITING · Early Phase 1
-
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
RECRUITING · Early Phase 1
-
FES BPET-DBT in Newly Diagnosed Breast Cancer
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI